贫血、白细胞增多和血小板增多作为宫颈癌根治性放化疗患者的预后因素:一项回顾性队列研究
结果显示,治疗前和治疗中贫血均与5年无进展生存期(PFS)和总生存期(OS)显著较差相关,贫血合并白细胞增多或NLR升高时不良影响更显著;治疗前贫血改善至正常血红蛋白水平的患者PFS和OS更好。
要点
- 治疗前和治疗中贫血均是宫颈癌放化疗患者5年PFS和OS较差的显著独立预测因素。
- 治疗前贫血合并白细胞增多或NLR升高时,对5年PFS和OS的不良影响更显著。
- 治疗前贫血在治疗中改善至正常血红蛋白水平的患者,5年PFS和OS优于持续贫血者。
核心结论
- 治疗前和治疗中贫血是宫颈癌根治性放化疗患者5年PFS和OS较差的显著独立预测因素。
- 贫血及其他血液学参数仍是宫颈癌患者的预后标志物。
- 血红蛋白恢复正常与PFS和OS改善相关。
研究设计与样本
- 患者接受放化疗(CRT)和近距离放疗。
主要发现
- 治疗前贫血(血红蛋白≤115 g/L)与5年PFS较差相关(60% vs 34%,p < 0.0001)和OS较差相关(68% vs 41%,p < 0.0001)。
- 治疗中贫血与5年PFS较差相关(62% vs 40%,p < 0.0001)和OS较差相关(70% vs 48%,p < 0.0001)。
- 治疗前贫血合并白细胞增多(白细胞计数>10 × 109/L)患者5年PFS为72% vs 42%(p < 0.0001),OS为68% vs 37%(p < 0.0001)。
- 治疗前贫血合并NLR升高(比值>5)患者5年PFS为61% vs 30%(p < 0.0001),OS为68% vs 37%(p < 0.0001)。
- 治疗前贫血在治疗中改善至正常血红蛋白水平的患者5年PFS为50% vs 31%,OS为60% vs 36%,优于治疗前和治疗中均贫血者。
关键数值与推荐
- 贫血定义为血红蛋白≤115 g/L。
- 白细胞增多定义为白细胞计数>10 × 109/L。
- 血小板增多定义为血小板>400 × 109/L。
- NLR升高定义为比值>5。
临床怎么用
- 治疗前和治疗中应关注血红蛋白水平,贫血可作为预后分层指标。
- 对治疗前贫血合并白细胞增多或NLR升高的患者应加强监测和预后评估。
- 治疗中血红蛋白恢复正常的患者预后更好,提示纠正贫血可能改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematologic parameters have emerged as potential indicators of worse outcome in this patient group. In a cohort of cervical cancer patients treated with chemoradiotherapy (CRT) and brachytherapy, we report on the prognostic significance of hematologic parameters including anemia, leukocytosis, neutrophil to lymphocyte ratio (NLR), and thrombocytosis, the effect of combining anemia with other hematologic parameters, and the effect of changes in hemoglobin levels during treatment. MATERIALS AND METHODS: Two-hundred fifty-seven cervical cancer patients were retrospectively identified from a single cancer institution's database. Hematologic parameters were categorized as: anemia (hemoglobin ≤115 g/L), leukocytosis (white blood cell count >10 × 109/L), thrombocytosis (platelets >400 × 109/L), and NLR (ratio >5). The association between clinical factors and hematologic parameters on progression-free survival (PFS) and overall survival (OS) were assessed at 5 years. RESULTS: At 5 years, both pre-treatment anemia (PFS: 60% vs 34%, p < 0.0001; OS: 68% vs 41%, p < 0.0001) and on-treatment anemia (PFS: 62% vs 40%, p < 0.0001; OS: 70% vs 48%, p < 0.0001) were significantly associated with worse survival. This adverse effect on 5-year PFS and OS was increased in patients with both pre-treatment anemia and leukocytosis (PFS: 72% vs 42%, p < 0.0001; OS: 68% vs 37%, p < 0.0001) and pre-treatment anemia and elevated NLR (PFS: 61% vs 30%, p < 0.0001; OS: 68% vs 37%, p < 0.0001). Five-year PFS (50% vs 31%) and OS (60% vs 36%) was better in patients whose pre-treatment anemia improved to normal hemoglobin levels on treatment vs those patients who were anemic both pre- and on-treatment. CONCLUSION: Pre-treatment and on-treatment anemia were significant, independent predictors of worse PFS and OS. Anemia and other hematologic parameters remain prognostic markers for cervical cancer patients. Improvement in PFS and OS was seen in patients with normalization of hemoglobin.
引用
- Koulis TA, Kornaga EN, Banerjee R, et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study. Clin Transl Radiat Oncol. 2017. PMID: 29594208. doi:10.1016/j.ctro.2017.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。